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CObjective: To describe the development and validation of a health eco-
nomic model (HEM) to address the tobacco disease burden and the
cost-effectiveness of smoking cessation interventions (SCI) in seven
Latin American countries. Methods: The preparatory stage included
the organization of the research network, analysis of availability of
epidemiologic data, and a survey to health decision makers to explore
country-specific information needs. The development stage involved
the harmonization of a methodology to retrieve local relevant param-
eters and develop the model structure. Calibration and validation was
performed using a selected country dataset (Argentina 2005). Predicted
event rates were compared to the published rates used as model in-
puts. External validation was undertaken against epidemiologic stud-
ies that were not used to provide input data. Results: Sixty-eight deci-
ion makers were surveyed. A microsimulation HEM was built
onsidering the availability and quality of epidemiologic data and rel-
vant outcomes conceived to suit the identified information needs of O
e no
Clin
al So
doi:10.1016/j.jval.2011.05.010ecision makers. It considers all tobacco-related diseases (i.e., heart,
erebrovascular and chronic obstructive pulmonary disease, pneumo-
ia/influenza, lung cancer, and nine other neoplasms) and can incor-
orate individual- and population-level interventions. The calibrated
odel showed all simulated event rates falling within  10% of the
ources (-9%–5%). External validation showed a high correlation be-
ween published data and model results. Conclusions: This evidence-
ased, internally and externally valid HEM for the assessment of the
ffects of smoking and SCIs incorporates a broad spectrum of tobacco
elated diseases, SCI, and benefit measures. It could be a useful policy-
aking tool to estimate tobacco burden and cost-effectiveness of SCI.
eywords: cost-effectiveness, cost-utility, disease burden, economic
odel, Latin America, Monte Carlo microsimulation, smoking cessa-
ion interventions, tobacco, validation.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Smoking is the single most preventable cause of disease and death
worldwide, and this burden is increasingly shifting from upper to
lower andmiddle-income countries. In the year 2000 therewere 4.83
million premature tobacco-related deaths [1], and this number is ex-
pected to grow to 10 million per year by 2030 [2,3]. Currently half of
the current tobacco-attributable deaths occur in high-income coun-
tries [1,3]; however, by the year 2030 7 out of 10 of these deaths are
expected to occur in developing countries. This represents one out of
six of all the deaths around the world [3].
Conflicts of interest: The authors have indicated that they hav
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1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.Although the Framework Convention Tobacco Control from
World Health Organization has been signed by almost every coun-
try in the Latin American region [4], tobacco control policies are
still scarce in these countries.
The lack of quality information related to the health and
economic consequences of tobacco use in our region is an im-
portant barrier for the implementation of evidence-based to-
bacco control policies. This has led to a biased assessment by
policy makers, resulting in a distorted prioritization of health
policies where tobacco control interventions are considered
less urgent than action on other diseases [5].
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accepted as decision-making tools [6] that can provide valuable
information for the optimization of health resource allocation
[7]. Although in many developed countries this “fourth hurdle”
based on health economic evidence is required to shape health
policies [8], there is still little experience in Latin America [9].
This project constitutes a collaboration among seven Latin
American countries that aims to provide relevant evidence to
inform tobacco control policies.
The LatinCLEN Tobacco Research Group, an international
and interdisciplinary network, is composed of eight research
units from the Latin American chapter of the International Clin-
ical Epidemiology Network in Argentina, Bolivia, Brazil, Chile,
Colombia, Mexico, and Peru. The specific aims for this project
were to select and develop the most suitable methodologic
framework, as well as to elaborate a common health economic
model to estimate the smoking-related disease burden and the
cost-effectiveness of smoking cessation interventions (SCIs). In
this article we present the details of the model’s development,
structure, and validation using data inputs from one of the par-
ticipating countries.
Material and Methods
The final model structure and its inputs were agreed after two
stages; the preparatory stage and the development stage.
Preparatory stage
Organization of a research network to monitor the model build-
ing process and to ensure the generalizability to all participant
countries. The LatinCLEN Tobacco Research Group was formed in
004. The group designed two surveys that were completed in
ach country to 1) evaluate the availability, cost, and current cov-
rage policies of SCIs; and 2) assess the availability and the quality
f relevant information to be incorporated in each country-spe-
ific analysis (e.g., local epidemiology and cost of smoking-related
iseases).
Performance of a rapid systematic review of existing health eco-
nomic evaluations regarding tobacco cessation strategies. Forty-
our individual studies and seven reviews published between 1984
nd 2003 (search data up to November 2004) were critically as-
essed.
Design and administration of a survey to health decision makers
to explore country-specific information needs when deciding on
the implementation and coverage of SCIs. As future users of the
EE, relevant decision makers from the different health sectors
n the seven participant countries defined the key aspects to be
onsidered (e.g., relevant time horizon and relevant perspec-
ive) and the outcomes to be reported (e.g., the number of cases
revented, life years gained, or quality-adjusted life years
QALYs]) in the HEE.
Development stage
This stage involved the following tasks: 1) definition of the meth-
odology for the information source selection and parameter incor-
poration; 2) development of themodel structure; and 3) calibration
and validation of the model.
The research group used Email and a Web-based platform to
exchange documents, outlines, and ideas. The development of
the model was completed in three phases: 1) based on informa-
tion obtained in the preparatory stage, a first draft of the health
economic model was sent to the participating countries forfeedback, including the basic structure, disease states to be in-
corporated, and main assumptions; 2) three consultation
rounds for refining the model description and structure; and 3)
a face-to-face research meeting carried out in Buenos Aires,
Argentina, during November 2006 where participants agreed on
the final version of the HEE.
Excel (Professional Edition 2003, then updated to version 2007,
Microsoft Corp., Redmond, WA) with Visual Basic Macros (version
6.3, Microsoft Corp., Redmond, WA) was selected as the model
platform to easily share the information. A software package was
installed to improve the original Excel’s random number genera-
tor function [10,11].
Results
Preparatory stage
The surveys and data retrieved in each country showed that
implementation of tobacco control interventions was a relevant
issue in the region. Sixty-eight decision makers (9–10 from each
of the participating countries) completed the survey. The ma-
jority of decision makers belonged to the public (56%) or the
social security (25%) health care sector and 80% considered that
the lack of coverage for SCI adversely affected the prevalence of
smoking in their institutions and countries. Ninety-three per-
cent considered that this level of coverage should be increased
and 83.3% believed that SCI should be included in the national
lists or basket of mandatory coverage in their countries. When
asked about what would be the most relevant information on
the interventions needed when having to decide their incorpo-
ration into the health system,most of the decisionmakers iden-
tified the cost per QALY, cost per life-year saved, and budget
impact information. The decision makers also mentioned a
wide range of interventions that they considered should be
evaluated for coverage, from population-wide interventions to
pharmacological treatments, so the HEE had to be able to in-
clude all these aspects. On the other hand, the survey of epide-
miologic data showed that the availability and quality of infor-
mation in the region was very heterogeneous and poor,
especially with regard to the incidence of events, thus making it
necessary to design and harmonize a methodology to estimate
locally relevant information in each country. All the results ob-
tained during this first stage strongly influenced many of the
decisions made later and shaped the type and structure of the
model to be developed.
Development stage
Information source selection and parameter incorporation. We
defined a decision rule thatwould establish a priority order among
the possible data sources to populate the model: 1) use good qual-
ity local (country-specific) sources when available [12-14]; 2) use
international sources when local data were unavailable or poor
and when the parameter was considered transferable from other
settings; or 3) derive or estimate the parameter from the best avail-
able local data when international sources were considered non-
transferable.
Special attentionwas paid to the estimation of baseline disease
event incidence in nonsmokers because these data are keys to the
generalizability of the model. Given the low availability of infor-
mation encountered in the region, we defined a commonmethod-
ology, anchored on national health statistics, to derive these pa-
rameters from mortality data. This methodologic assumption
linking mortality to incidence data is a widely used assumption in
epidemiologic and health economic models, used by the World
Health Organization in tools such as DisModII or the WHO-
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S53V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) S 5 1 – S 5 9CHOICE, and by GLOBOCAN [15-20]. Different approaches were
taken for acute events or chronic conditions. For acute events,
such as cardiac or cerebrovascular events, the first step was to
obtain the age-, sex- and country-specific absolute risk of the
event based on the specific mortality rate and the lethality of the
event:
Rpop.event
Rdeath
L
(1)
where L is the lethality of the event and Rdeath is the age- and
ex-specific mortality of the condition. Once this absolute risk is
nown, the baseline risk in nonsmokers was calculated based on
he age-, sex- and country-specific smoking prevalence as well as
isease-specific smoking relative risk:
nosmk
Rpop.event
(RRsmk fsmk) (RRformersmk fformersmk) fnosmk
(2)
where Rnosmk is the baseline event annual incidence in non-smok-
rs, Rpop.event is the age- and sex-specific population risk (obtained
ith formula 1), RRsmk and RRformersmk are the relative risks of the
event in smokers and former-smokers versus nonsmokers, and
ƒsmk, ƒformersmk and ƒnosmk are the age- and sex-specific proportion
f smokers, former-smokers, and nonsmokers. For cancer (as
hronic conditions), the age and sex estimation of the probability
f diagnosis was calculated using a more complex approach that
onsidered both the annual mortality rate from national statistics
s well as the estimated yearly survival rate since diagnosis. The
ge- and sex-specific risk of diagnosis for each cancer was calcu-
ated with the following formula:
dxi 
n0
10
Rmi Pn 1
1 S10
(3)
here Rdxi is the risk of diagnosis at age i; Rmin is the population
isk of death from the specific cancer at age in; Pn is the condi-
ional probability of dying in year n after the diagnosis, conditional
n dying within 10 years; and S10 is the proportion of survivors
after 10 years. We assumed that those subjects surviving 10 years
after a lung cancer diagnosis, or five for other cancers, return to the
general population risk of death. Then, the formula (2) was applied
to derive the baseline risk in nonsmokers.
A special case was chronic obstructive pulmonary disease
(COPD). Because national statistics are known to significantly un-
derestimate COPD-related mortality, we estimated its incidence
and prognosis based on international studies [21,22].
Model structure and operation. A first order Monte Carlo, or prob-
abilistic microsimulation of individual subjects, was built. This
model incorporates the natural history, costs, and quality of life of
all the tobacco-related adult-specific diseases: coronary and non-
coronary heart disease, cerebrovascular disease, COPD, pneumo-
nia, influenza, lung cancer, and nine other neoplasms. Thismodel
allows the follow-up of the lives of thousands of individuals in
hypothetical cohorts, calculating all outcomes for each patient in
an annual basis, using the simulation of each individual’s history
to ultimately obtain aggregated population results in terms of
health and costs. Subjects can be assigned demographic and dis-
ease specific characteristics. The model updates the values of the
various input parameters for each patient in a yearly basis and
calculates event rates for outcomes on the basis of the variables
and the underlying risk equations.
The model runs on Visual Basic and captures the key parame-
ters from four main spreadsheets: 1) sex- and age-specific epide-
miologic data; 2) unit cost; 3) quality of life; and 4) interventions
effects. It consists of two main modules. The first one is used for
the analysis of the disease burden associated with smoking, in
which age and sex detailed information of selected epidemiologicand economic data is kept (e.g., the number of events suffered by
the cohort throughout specific ages, the distribution of COPD
stages or the prevalence of coronary heart disease). The second
module is the one that performs the cost-effectiveness analysis,
and it focuses on the comparison of the experience of two cohorts
for whom different sets of interventions are defined. The cohorts
are then followed during their lifetime, and the aggregated results
are compared in terms of costs and benefits.
Disease incidence, progression, and mortality. For each time pe-
iod, the model estimates the individual risks of occurrence of
ach event, disease progression and death, based on the subject’s
emographic attributes, smoking status, and clinical conditions.
able 1A shows a list of possible events a subject can suffer in each
ime period and the calculation method used to derive it. Table 1B
hows the different health states considered in themodel. The risk
f death is calculated for each time unit as the age- and sex-spe-
ific general mortality, excluding the 16 disease-specific risks of
eath considered in themodel, plus the risk of death of the events
nd conditions that the individual experiences during that time
nit (Table 1C).
For instance, in the case of myocardial infarction the model
stimates its riskmultiplying the age-and sex-specific risk in non-
mokers (baseline incidence) in each time period and for each
ubject, by the relative risk related to his smoking status. Then, a
andom number is generated; if this number is less tan or equal to
he individual probability, the model assumes that the event is
resent. The risk of death, in this case, will be the general risk of
eath plus the myocardial infarction age- and sex-specific case
atality.When there ismore than one simultaneous cause of death
or a given subject in the same time period, a probabilistic ap-
roach is used to assign the final cause of death, weighted by the
aseline risk of each competing cause.
For COPD, besides the risk of acquiring this condition, the risk of
rogression to more severe stages in those already affected is esti-
ated according to the individual’s smoking status. For oncologic
onditions, the specific risk of death is estimated according to the
umberof years sincediagnosis. This typeof individual-basedmodel
llows for having multiple events in a given year, as they are not
utually exclusive. This was the main reason to choose this model
nstead of a state transition cohort model (i.e., Markov cohort).
Smoking status and interventions. We considered three smok-
ng status states: current smokers, former smokers, and never
mokers. Smokers have a given probability of making a quit
ttempt in each time unit as well as a probability of succeeding
n that attempt without any active intervention (background
uitting rates). These probabilities are age- and sex-related, and
n case of considering a population SCI, its effect could be mod-
led by directly influencing this background quitting rate (Table
A). Similarly, former smokers have a given relapse probability
elated to the time elapsed since the successful quit attempt
background relapsing rates). The model was built to consider a
ide range of intervention modalities: 1) interventions/policies
ith the objective of improving smoking cessation rates in
mokers who have a quit attempt (e.g., nicotine replacement or
ehavioral interventions); 2) interventions/policies that in-
rease the probability of smokers attempting to quit (e.g., media
ampaign) and; 3) mixed interventions/policies that influence
oth the probability of attempting to quit and the success rates
e.g., training primary care physicians in brief counseling inter-
entions, including pharmacotherapy in benefit plans).
Resource use, cost, and quality of life. The model is programmed
to calculate the use of resources and the QALYs in each time unit
as a summary of the events the subject experienced in that par-
ticular time unit with the active health conditions coming from
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S54 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) S 5 1 – S 5 9prior time units. Costs and QALYs are simultaneously calculated
in undiscounted and discounted fashions.
Main assumptions. The occurrence of all the modeled events is
independent and not mutually exclusive. In the case of coexistence
of two ormore events or conditions, the costs and the absolute risks
of death are additive and theQALYs aremultiplicative. Each event or
condition has two sets of cost and QALYs estimates: one for the first
year and the other for the subsequent years up to a customized spe-
cific timehorizon. In the current version, this timehorizonwas set to
a lifetime for the cardiovascular events andCOPD, to 10 years in lung
cancer, and to 5 years in all other neoplasms. Cancer survival was
modeledasdependantof sexand theyears sincediagnosis, indepen-
dent of age. COPD incidence was modeled as dependant of sex, age,
and smoking status; its progression as dependant of sex, years in
current stage, and smoking status. COPD deaths were modeled as
dependant of sex and stage.
Model outputs. Results can be presented according to age, sex,
revious cardiovascular history, and other specific epidemio-
ogic data. Different benefit measures that can be used to report
he cost-effectiveness of the different smoking cessation strat-
gies are cost per quitter; cost per year of life gained, cost per
vent averted, and cost per QALY. To reflect decision uncer-
ainty, a graphical depiction of the results of several simula-
ions (second-order uncertainty) each comparing a specific pop-
lation of interest (first-order uncertainty) can be made. This
an be shown in the cost-effectiveness plane as the incremental
ost-effectiveness rate dispersion, as 95% confidence intervals,
Table 1 – (A) Acute events, (B) chronic disease states, and (
A. Acute events B. Ch
diseas
Disease acute events
MI
Non MI CHD event
Stroke
COPD diagnosis
COPD progression
Pneumonia/Influenza
Cancer diagnosis: lung, bladder, renal, lip/oral/pharynx,
larynx, stomach, esophagus, pancreas, cervical
cancer, leukemia
Smoking behavior events
Performing a quit attempt
Succeeding in a quit attempt
Relapsing after successful quit attempt
Probability calculation
Disease events:
Baseline Risk in non-smokers (age/sex specific) x
RRsmoking.status
COPD progression:
Baseline Risk in non-smokers (sex and years-in-
previous-stage specific) x RRsmoking.status
Performing or succeeding quit attempt:
Baseline population probability (age/sex specific) x
RR.INTERVENTION
Relapsing:
Risk based on years in former-smoker state (sex
specific)
CHD pati
Post - Str
COPD Sta
Lung can
Bladder c
Renal can
Lip/oral/
cancer
Larynx c
Stomach
Esophagu
Pancreas
Cervical
Leukemi
Smoking
Smoke
Former
Never
CHD, coronary heart disease; COPD, chronic obstructive pulmonary d
relative risk of the intervention (either to improve the probability of pe
RRsmoking.status, disease specific relative risk according to smokingnd also as cost-effectiveness acceptability curves to show the srobability of each strategy being cost-effective according to
ocally relevant threshold values. To perform a probabilistic
ensitivity analysis, the probability distribution of selected pa-
ameters are incorporated into the model. For each iteration,
arameters values are recalculated and applied to the equa-
ions. In Figure 1 we present an example of the cost-effective-
ess results of two hypothetical SCIs in 500 simulations of 5000
0-year old men.
Different one-way or scenario sensitivity analyses can also be
ncorporated for the estimation of the effects of selected parame-
ers. The detailed information provided by the model can also be
sed to perform budget impact analysis and to guide for locally
elevant research priority setting [23,24].
Calibration and validation
We applied the International Society for Pharmacoeconomics
and Outcomes Research criteria for model development and
reporting [25]. The model structure and the parameters’ calcu-
lation approach were validated and calibrated using a selected
country dataset (Argentinean National Health Statistics year
2005) [26].
Internal validation. Internal testing and debugging were per-
ormed to ensure that the mathematical calculations were ac-
urate and consistent with the specifications of the model. The
odel was checked and tested during the modeling process to
dentify any errors relating to data incorporation and modeling
uses of death included in the model.
c
tes
C. Causes of death
r
nx
er
cer
er
r
s:
ker
ed
MI
Non MI CHD event
Stroke
Pneumonia/Influenza
Non-ischemic CV death
COPD
Lung cancer
Bladder cancer
Renal cancer
Lip/oral/Pharynx cancer
Larynx cancer
Stomach cancer
Esophageal cancer
Pancreas cancer
Cervical cancer
Leukemia
Mortality for all other causes
Probability calculation
Acute events deaths:
Probability of the event x its lethality (age/sex specific)
Non-ischemic CVD death:
Baseline Risk in non-smokers (age/sex specific) x
RRsmoking.status
COPD:
Stage specific mortality (sex specific)
Cancer:
Tumor annual specific mortality during the first five years
after diagnosis (except lung cancer: 10 years)
Mortality for all other causes
General population mortality minus the mortality of the
diseases included in the model (sex and age specific)
e; CV,cardiovascular; MI, Myocardial infarction; RR.INTERVENTION,
ing a quit attempt or to improve the success rate of the quit attempt);
s.C) ca
roni
e sta
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S55V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) S 5 1 – S 5 9replication using equivalent input values was applied. Inconsis-
tencies were detected and programming errors corrected.
Calibration. Calibration was performed to ensure that the model
can reproduce the results of the sources used to run the model.
General mortality and all age- and sex-specific death rates pre-
dicted by the model were compared with local health statistics,
with a total of 16 parameters (excluding COPD mortality, univer-
sally agreed to be underestimated in national statistics) [21,22].
Sex- and age-specific model outputs were compared to the source
rates and deviations from the expected values were analyzed.
Mean simulated event rates within  10% of the mean reference
event rates were considered acceptable, and in cases of higher
deviations, the risk equation for that particular event was modi-
fied to provide a better fit to the published data. The search
stopped as soon as all the outputs were within 10% of the target
results. As explained earlier, the disease event incidence was es-
timated from the age- and sex- specific mortality and the lethality
of the event for acute conditions andCOPD, and the yearly survival
(a)          (b) 
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Fig. 1 – (A) Cost effectiveness plane of cost- and effect-
related differences between two smoking cessation
interventions (SCI). SCI-a: cost $472, effectiveness: 15%
smoking cessation at 1 year; SCI-b: cost $1.254,
effectiveness: 23% smoking cessation at 1 year
(Argentine pesos 2007). Preliminary results for 500
simulated cohorts of 5000 50-year old male smokers
after one quit attempt. Discount rate for costs and
effects: 5%. (B) Cost-effectiveness acceptability curve
showing the probability that SCI-b is cost-effective as
compared to SCI-a over a range of values for the
maximum acceptable ceiling ratio.
Table 2 – Baseline annual risk in nonsmokers: data source
calibration process.
Parameter Calculation process
Baseline event incidence
in nonsmokers – acute
conditions (stroke,
cardiac events,
Pneumonia/Influenza)
Formula 1 and Formula 2 – A
– Le
– Sm
– D
s
Baseline cancer incidence
in nonsmokers
Formula 3 and Formula 2 – A
– Su
– Sm
– D
s
Baseline risk of COPD
incidence
Formula 2 – Po
s
– Sm
– D
s
Risk of death from all
other causes
AgeCOPD, chronic obstructive pulmonary disease.rate since diagnosis for cancers. These last twoparameters (lethal-
ity and survival rate) were estimated from local and international
studies and were allowed to vary  15% to determine the best
fitting parameter set. Table 2 describes the data sources, baseline
isk parameters calculation process, and the allowed variation
uring the calibration process. Besides ensuring that the simu-
ated results were within the prespecified range, the total number
f events and the event incidence were graphed for each parame-
er according to age and sex. The resulting observed and expected
urves were visually explored to confirm a good fit. Closeness of fit
as additionally assessed by plotting predicted versus observed
alues outcomes, fitting a linear curve through the points with the
ntercept set at zero, and obtaining a squared linear correlation
oefficient (R2). The final simulation set was composed of 20 co-
orts (10 of men and 10 of women) of 25,000 continuing smokers,
5,000 smokers who quit smoking during follow-up and 25,000 life-
ong nonsmokers followed through their lifetime. The sample size of
he simulations was estimated on the basis of the standard error of
heparameterwith greater variability (lifelong risk of death fromoral
avity cancer) to be able to obtain 95% confidence intervals within
0% in each cohort (smokers, former smokers, and nonsmokers). In-
idence rates estimated from the simulated cohorts were trans-
ormed into absolute numbers of events in each age and sex strata
ollowing Argentina 2005 population distribution [26]. After calibra-
ion, the differences between published data and the model results
anged from -9% to 5%. The curves’ shapes of the age- and sex-
pecific simulated number of events adequately overlapped with
hose of the expected values, showing, in all cases, an excellent in-
ernal validity. Figure 2 shows results in four conditions: myocar-
ial infarction, kidney cancer, nonischemic cardiovascular dis-
ase, and oral cavity cancer. As expected, correlation between
redicted and observed results was better among high inci-
ence events (such as myocardial infarction, stroke, or lung
ancer) and weaker for less frequent (thus with greater variabil-
ty) events such as leukemia or oral cavity cancer. When pre-
icted values were plotted against observed data to assess
oodness of fit, the majority of values were on or close to the y
line, indicative of perfect fit. Evaluation of the correlation be-
ween predicted and observed data produced R2 values that
ranged from 0.758 to 0.999 (perfect fit  1) indicating a very
strong correlation. The regression lines obtained for the 16 pa-
rameters ranged from a gradient of 0.874 to 1.272, close to the
lculation process and allowed variation during the
Data inputs Source Allowed
variation
d sex-specific mortality
ty
g prevalence
specific RR for smokers and former
rs
[26], [36]
[37], [38]
[33]
[39]
None
 15%
None
None
d sex-specific mortality
l rate
g prevalence
specific RR for smokers and former
rs
[26]
[16], [17]
[33]
[39]
None
 15%
None
None
tion COPD incidence (age and sex
c)
g prevalence
specific RR for smokers and former
rs
[21], [22]
[33]
[39]
 15%
None
None
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S56 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) S 5 1 – S 5 9perfect fit line (gradient  1). These results are shown in Figure
for stroke, lung cancer, pancreatic cancer, and esophageal
ancer.
External validation. Model results were validated against selected
ublished epidemiologic and clinical studies not used to provide in-
ut data. Stroke and myocardial infarction age- and sex- specific
vent rates predicted by model were compared with those from in-
ernational and local available data: the World Health Organization
ONICA Project data on stroke andmyocardial infarction incidence
World Health Organization monitoring of trends and determinants
n cardiovascular disease) [27,28] and the only population-based
yocardial infarction incidence study performed in Argentina
29,30] (see Fig. 4A and Fig. 4C). Age- and sex-specific COPD predicted
revalence was compared with the results from the Latin American
roject for the Investigation of Obstructive Lung Disease, a popula-
ion-based study carried out in five LatinAmerican cities [31] (see Fig.
B). Lung cancer incidence and lung cancer mortality predicted by
he model were compared to those of the global cancer estimations
eported by the International Agency for Research on Cancer [16,17]
see Figs. 4D and 4E). As a final endpoint that is influenced by the
thers, the toll on life expectancy of smokers and former smokers
redicted by themodelwas analyzed togetherwith the effect of quit-
ing smoking at age 55 years. Results were compared to the popula-
Fig. 2 – Calibration: Annual number of deaths predicted by t
Argentinean national health data [26] in four selected condit
(women); (C) non-ischemic cardiovascular disease (men) andion-based study of male British doctors [32] (see Fig. 4F). In all caseshigh correlation between published data and model results was
bserved.
Discussion
Smoking is thesinglemostpreventablecauseofdiseaseanddeathall
around the world [1]. In Latin America tobacco control policies are
still poor andaccess to SCI is very limited [33-35]. In a context ofmore
limited resources local evidence from cost-effectiveness studies is
essential to implement more efficient health policies. Although in-
ternational evidence regarding the burden of tobacco-related dis-
eases is extensive, it is widely known that the results of health eco-
nomic evaluations cannot be directly transferred fromone setting to
another. Recently, countries such as the United Kingdom have
changed tobacco intervention policies using cost-effectiveness data,
suggesting that the presence of regional, accurate information in
Latin America could lead to an increased availability of effective in-
terventions and a better definition of local research priorities.
Our study describes the development and validation of a HEE
model to evaluate the disease burden associated with smoking
and the cost-effectiveness of SCIs in Latin America. To ensure
the local relevance of this model, decisionmakers and research-
ers from each participant country provided input from the be-
odel in Argentina for each age strata compared to the 2005
: (A) myocardial infarction (women); (B) kidney cancer
oral cavity cancer (men).he m
ions
; (D)ginning of the project. The main characteristics of the HEE were
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S57V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) S 5 1 – S 5 9defined taking into consideration the availability and quality of
the required epidemiologic data in the region. The relevant out-
comes of the HEE model were conceived to suit the different
policy makers’ information needs identified in the preparatory
stage of the study. The HEE model showed internal validity with
all simulated event rates falling within  10% of the source
ublications and it also showed an excellent external validity
hen model results were compared to selected published stud-
es. This external validation considered different conditions an-
lyzed from different perspectives: death incidence, disease
revalence, and survival experience of the simulated cohorts.
his comprehensive validation process is reassuring regarding
he adequate performance of the model. It showed to be a reli-
ble tool that can be used to estimate the tobacco-related dis-
ase burden and the cost-effectiveness of different SCI in the
articipant countries.
It is important to note that the validation that we are present-
ng here corresponds to a single country data set (Argentina), and
hat a similar validation process is required for each country in
hich the model is applied.
This is the first multicountry collaborative project that, to our
nowledge, developed and validated amicrosimulationmodel ca-
able to evaluate the cost-effectiveness of a wide range of SCIs in
atin America, from public health interventions to specific indi-
idual therapies. As opposed tomost published tobacco economic
odels that are based on state transition structures, the main
dvantages of the microsimulation-based approach include the
ossibility of tracking each subject’s history (as opposed to the
memorylessness” ofMarkovmodels) andhow it influences future
vents; the possibility of simultaneously experiencing different
ealth states during follow-up (which would render a Markov
odel nearly unmanageable); and being intrinsically probabilistic,
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Fig. 3 – Correlation plot of model predicted versus reported a
(women); (B) lung cancer (men); (C) pancreatic cancer (wome
lines (y) and the correlation coefficients (R2) are reported in e
tatistics year 2005 [26].llowing todepict first order (person-level) uncertainty. Secondorder nparameter-level) uncertainty can be estimated in the probabilistic
ensitivity analysis through the incorporation of defined distribu-
ions in selected parameters. In addition, it can be easily adapted to
ew information availability. Whereas other tobacco-related eco-
omicmodels are usually limited to cardiac disease and lung cancer,
ur model included most tobacco-related diseases and additionally
ncompassed cerebrovascular disease, COPD, pneumonia, and influ-
nzaaswell asnineotherneoplasms. It alsoallowed incorporationof
ackground quitting and relapsing rates.
Some considerations and possible limitations to our model in-
lude the following: 1) it is highly dependent upon local health
tatistics, which may, in some settings, misestimate the actual
isease-specific toll; 2) it does not analyze the effect of second-
and smoking; and 3) it does not incorporate the effect of tobacco
n mother and child health.
This project was supported by grants from international
gencies, allowing us to develop a generic tool not oriented to a
articular SCI. In addition, because this model was designed
aking into consideration the low availability and quality of in-
ormation in the seven participant countries, it could be easily
dapted to be used in other “information-poor” settings such as
ost low and middle income countries.
Apart frombeing able to depict the incremental cost and effect of
nterventions for the economic evaluation, themodelwas conceived
s a tool to provide burden of tobacco-related diseases and budget
mpact data. This is of utmost relevance to raise awareness of the
ealth and economic consequences of smoking in the region. The
eed to more precisely estimate the burden of the smoking-associ-
ted diseases measured in terms of economics and clinical conse-
uences (smoking related illnesses and quality-adjusted survival)
till exists. Also, it is highly important to incorporate these tools in
atin America to inform decision makers about the cost-effective-
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